Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6019426 | 0.85 | ECE1 (0.49) | ECE1PTGDR2 | |
| SCHEMBL8334899 | 0.84 | ECE1 (0.68) | ECE1 | |
| SCHEMBL6174014 | 0.82 | PPARG (0.40) | ECE1PTGDR2 | |
| SCHEMBL8338253 | 0.82 | ECE1 (0.64) | ECE1 | |
| SCHEMBL8328651 | 0.82 | ECE1 (0.77) | ECE1 | |
| SCHEMBL8362876 | 0.81 | ECE1 (0.58) | ECE1 | |
| SCHEMBL8362921 | 0.80 | ECE1 (0.61) | ECE1 | |
| SCHEMBL6019416 | 0.78 | ECE1 (0.63) | ECE1 | |
| SCHEMBL8362917 | 0.77 | ECE1 (0.68) | ECE1 | |
| SCHEMBL8334902 | 0.77 | ECE1 (0.61) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183753-A1 | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | BAYER HEALTHCARE AG (DE) | 2006-08-17 | — | — | US | disclosed |
| US-7045544-B2 | Substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2006-05-16 | — | — | US | disclosed |
| EP-1578418-A2 | USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES | Bayer HealthCare AG (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20050038101-A1 | Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2005-02-17 | — | — | US | disclosed |
| WO-2004056768-A2 | USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003028719-A1 | SUBSTITUTED 2,5-DIAMIDOINDOLES AS ECE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183753-A1 | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | DCK, UROD, QDPR | ECE1 756/4885PTGDR2 286/4885 |
| US-20050038101-A1 | Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases | ECE1, ECE2, EDNRA | ECE1 1/4885PTGDR2 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.